Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibodies With Simultaneous Subsite Specificities to Protein and Lipid Epitopes, 6814 [2013-02097]

Download as PDF srobinson on DSK4SPTVN1PROD with 6814 Federal Register / Vol. 78, No. 21 / Thursday, January 31, 2013 / Notices • Testimony from representatives of the military criminal investigation organizations. • Testimony from subject matter experts on the military justice system. • Receipt of public comments—3:00 p.m. to 4:00 p.m. Availability of Materials for the Meeting: A copy of the agenda for the February 15, 2013 meeting and the tasking for the Subcommittee may be obtained at the meeting or from the Board’s Staff Director at StaffDirectorDefenseLegalPolicyBoard@ osd.mil. Public’s Accessibility to the Meeting: Pursuant to 5 U.S.C. 552b and 41 CFR 102–3.140 through 102–3.165, and the availability of space, part of this meeting is open to the public. Seating is limited and is on a first-come basis. Special Accommodations: Individuals requiring special accommodations to access the public meeting should contact the Staff Director at StaffDirectorDefenseLegalPolicyBoard@ osd.mil at least five (5) business days prior to the meeting so that appropriate arrangements can be made. Procedures for Providing Public Comments: Pursuant to 41 CFR 102– 3.105(j) and 102–3.140, and section 10(a)(3) of the Federal Advisory Committee Act of 1972, the public or interested organizations may submit written comments to the Board about its mission and topics pertaining to this public session. Written comments must be received by the Designated Federal Officer at least five (5) business days prior to the meeting date so that the comments may be made available to the Board for their consideration prior to the meeting. Written comments should be submitted via email to the address for the Designated Federal Officer in FOR FURTHER INFORMATION CONTACT in the following formats: Adobe Acrobat, WordPerfect, or Microsoft Word. Please note that since the Board operates under the provisions of the Federal Advisory Committee Act, as amended, all written comments will be treated as public documents and will be made available for public inspection. If members of the public are interested in making an oral statement, a written statement must be submitted as above along with a request to provide an oral statement. After reviewing the written comments, the Chairperson and the Designated Federal Officer will determine who of the requesting persons will be able to make an oral presentation of their issue during the open portion of this meeting. Determination of who will be making an oral presentation is at the sole discretion of the Committee Chair and the Designated Federal Officer and will VerDate Mar<15>2010 17:38 Jan 30, 2013 Jkt 229001 depend on time available and relevance to the Committee’s activities. Five minutes will be allotted to persons desiring to make an oral presentation. Oral presentations by members of the public will be permitted from 3:00 p.m. to 4:00 p.m. in front of the Board. The number of oral presentations to be made will depend on the number of requests received from members of the public. Committee’s Designated Federal Officer: The Board’s Designated Federal Officer is Mr. James Schwenk, Defense Legal Policy Board, PO Box 3656, Arlington, VA 22203. Email: defenselegalpolicyboarddfo@osd.mil. Phone: (703) 697–9343. For meeting information please contact Mr. David Gruber, Defense Legal Policy Board, PO Box 3656, Arlington, VA 22203. Email: StaffDirectorDefenseLegalPolicyBoard@ osd.mil. Phone: (703) 696–5449. Dated: January 25, 2013. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2013–02033 Filed 1–30–13; 8:45 am] BILLING CODE 5001–06–P Department of the Army Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibodies With Simultaneous Subsite Specificities to Protein and Lipid Epitopes Department of the Army, DoD. Notice. AGENCY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/525,574, entitled ‘‘Antibodies with Simultaneous Subsite Specificities to Protein and Lipid Epitopes,’’ filed on September 22, 2006. The United States Government as represented by the Secretary of the Army has rights to this invention. Foreign rights may be available. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. SUMMARY: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00012 Fmt 4703 Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2013–02097 Filed 1–30–13; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army; Army Corps of Engineers Notice of Intent to Prepare an Environmental Impact Statement for the Sacramento-San Joaquin Delta Islands and Levees Feasibility Study Department of the Army, U.S. Army Corps of Engineers; DoD. ACTION: Notice of intent. AGENCY: The action being taken is the preparation of an environmental impact statement (EIS) for the Sacramento-San Joaquin Delta Islands and Levees Feasibility Study (Delta Study). The EIS will be prepared in accordance with the National Environmental Policy Act (NEPA). The U.S. Army Corps of Engineers (Corps) will serve as lead agency for compliance with NEPA. The Delta Study will evaluate alternatives to meet the study goals of restoring sustainable ecosystem functions and improving flood risk management in the Delta, Suisun Marsh, and adjacent areas. DATES: Written comments regarding the scope of the environmental analysis should be received at (see ADDRESSES) by March 15, 2013. ADDRESSES: Written comments concerning this study and requests to be included on the Delta Study mailing list should be submitted to U.S. Army Corps of Engineers, Sacramento District, Public Affairs Office, Attn: Delta Study Scoping, 1325 J Street, Sacramento, CA 95814. FOR FURTHER INFORMATION CONTACT: The U.S. Army Corps of Engineers Public Affairs Office via telephone at (916) 557–7461, email at spkpao@usace.army.mil, or regular mail at (see ADDRESSES). SUPPLEMENTARY INFORMATION: 1. Proposed Action. The Corps is preparing an EIS to analyze the environmental impacts associated with alternatives for restoring sustainable ecosystem functions and improving SUMMARY: DEPARTMENT OF DEFENSE ACTION: The invention relates to a method of making antibodies that are dual specific to both (1) amino acid sequences and (2) solid phase lipid structures. The invention has relevance to such important subject matter as making broadly neutralizing monoclonal antibodies to HIV–1. SUPPLEMENTARY INFORMATION: Sfmt 4703 E:\FR\FM\31JAN1.SGM 31JAN1

Agencies

[Federal Register Volume 78, Number 21 (Thursday, January 31, 2013)]
[Notices]
[Page 6814]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02097]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Notice of Availability for Exclusive, Non-Exclusive, or 
Partially-Exclusive Licensing of an Invention Concerning Antibodies 
With Simultaneous Subsite Specificities to Protein and Lipid Epitopes

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Patent Application Serial No. 11/525,574, 
entitled ``Antibodies with Simultaneous Subsite Specificities to 
Protein and Lipid Epitopes,'' filed on September 22, 2006. The United 
States Government as represented by the Secretary of the Army has 
rights to this invention. Foreign rights may be available.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to a method of making 
antibodies that are dual specific to both (1) amino acid sequences and 
(2) solid phase lipid structures. The invention has relevance to such 
important subject matter as making broadly neutralizing monoclonal 
antibodies to HIV-1.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-02097 Filed 1-30-13; 8:45 am]
BILLING CODE 3710-08-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.